Analgesia Clinical Trial
Official title:
Comparison Perioperative Analgesia Efficacy Between Thoracolumbar Interfascial Plane Block and Erector Spinae Plane Block for Patients With Lumbar Spine Fusion Surgery: A Randomized Controlled Study
Background: Pain relief for lumbar spine surgery is being updated to help improve the quality of post-operative recovery, especially ultrasound-guided pain relief anesthesia methods, including two anesthesia methods. Thoracolumbar interfascial plane block (TLIP block) and erector spinae plane block (ESP block) are increasingly commonly applied. Objective: compare the pain relief effectiveness of TLIP block with ESP block for lumbar spine surgery. Methods: Randomized prospective intervention study conducted at Hanoi Medical University Hospital from October 2021 to October 2022 including 100 lumbar spine surgery patients randomly divided into three groups: group control, TLIP group and ESP group. Outcomes regarding perioperative pain score (ANIm, VAS), the effectiveness of 2 ultrasound-guided methods, the complications and the side effects were recorded.
- All research patients were divided into 3 groups by random drawing: control group, TLIP group and ESP group. - TLIP group: patients were anesthetized before surgery using TLIP lumbar block (L3) under ultrasound with 20ml of ropivacaine 0.25% anesthetic on each side. After that, the patient was given endotracheal anesthesia for surgery. - ESP group: patients were anesthetized before surgery with lumbar (L3) ESP block method under ultrasound with 20ml of Ropivacaine 0.25% anesthetic on each side. After that, the patient was given endotracheal anesthesia for surgery. - Control group: patients received regular endotracheal anesthesia, then the incision was anesthetized with 15ml of 1% lidocaine mixed with 1/200,000 adrenaline on each side before surgery. - Anesthesia and monitoring process: all patients in all 3 groups were anesthetized using general anesthesia: - Install monitoring to monitor pulse parameters, blood pressure, SpO2, EtCO2. - Install an Analgesia Nociception Index (ANI) meter and monitor the ANI index continuously during surgery. Monitor ANI monitor V2 during surgery, maintain ANIm within the range of 50-70. - Induction of anesthesia: fentanyl 2mcg/kg slow intravenous injection, wait 3 minutes then inject propofol 2-3mg/kg, rocuronium 0.6mg/kg (when eyelid reflex is lost). Proceed with endotracheal intubation and artificial ventilation at a frequency of 12 times/minute, Vt = 6-8ml/kg, FiO2 50%, I:E = 1:2, PEEP = 5cmH2O, EtCO2 = 35-45mmHg, sevoflurane Install until MAC reaches 0.8-1. - Maintain anesthesia with sevofluran, maintain 1 MAC. - Using fentanyl during surgery: when ANIm index is less than 50: 50mcg fentanyl bolus, repeat after 5 minutes until ANIm greater than 50. Record the amount of fentanyl used during surgery. Record the ANIm index at the time of the study: when skin incision (T0) and every 10 minutes until the end of surgery. - Release of anesthesia: Patients are extubated when they meet the criteria: awake, following orders, breathing rate 12-20 times/minute, SpO2 > 95% with FiO2 ≤ 40%, Vt > 5ml/kg, EtCO2 < 45 mmHg , good cough and swallow reflex and TOF ≥ 90%. After extubation, monitor the patient, record pulse index, blood pressure and VAS score and transfer the patient to the hospital room if it reaches 10/10 points according to Aldrete. - Pain relief: both groups received paracetamol 1g and ketorolac 30mg at the end of skin closure and every 8 hours thereafter. When the patient has postoperative pain (VAS score ≥ 4), they are titrated with intravenous morphine 1mg/time every 10 minutes until reaching a VAS score < 4. At the same time, an intravenous morphine pain relief machine is installed. Patient controlled analgesia (PCA) with bolus setting 1ml = 1mg, lockout time 10 minutes, maximum dose 20mg/4 hours, no background infusion dose. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05534230 -
Dexmedetomidine for Pain Reduction in CABG
|
N/A | |
Recruiting |
NCT06275698 -
HONEY for the Treatment of POst-Tonsillectomy Pain
|
N/A | |
Recruiting |
NCT04436224 -
Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation
|
Phase 4 | |
Not yet recruiting |
NCT04548323 -
Hypoalgesic Effects of Walking and Running Imagined
|
||
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT04394481 -
Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery
|
Phase 4 | |
Completed |
NCT04690647 -
The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement.
|
N/A | |
Completed |
NCT05034601 -
ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure
|
N/A | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05454202 -
Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
|
||
Recruiting |
NCT04554186 -
Serratus Anterior Plane Block Versus Thoracic Paravertebral Block.
|
N/A | |
Not yet recruiting |
NCT06393777 -
Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion
|
N/A | |
Suspended |
NCT04860635 -
Safety of F14 Following Total Knee Replacement
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Completed |
NCT02916342 -
Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks
|
Phase 4 | |
Completed |
NCT03206554 -
Local Infiltration Analgesia in Total Knee Arthroplasty
|
Phase 2 | |
Not yet recruiting |
NCT02549118 -
Tenoxicam for Intrapartum Analgesia
|
Phase 2 | |
Not yet recruiting |
NCT02190760 -
Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block.
|
N/A | |
Completed |
NCT01789606 -
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
|
Phase 3 | |
Completed |
NCT01299584 -
ULTIVA Post Marketing Surveillance
|
N/A |